ACS Biotech is focused on advancing regenerative medicine, particularly in the area of cartilage repair. The company has developed a patented cartilage gel that utilizes a unique 3D hydrogel chitosan matrix, which serves as a support for chondrocytes, the cells responsible for cartilage formation. This innovative product is designed for mini-invasive surgical procedures performed by specialized orthopedic surgeons, allowing for a single injection that aims to regenerate damaged articular cartilage. The technology promises to restore mobility and enable patients to return to their sporting activities within months post-surgery. Additionally, ACS Biotech is committed to conducting clinical studies to further validate the efficacy of their cartilage repair solutions.

In addition to their cartilage repair products, ACS Biotech also offers high-quality osteoarticular cells for research and development purposes, supporting studies focused on osteoarticular pathologies. The company has established expertise in the collection, conservation, and quality control of various osteoarticular cells, including chondrocytes and synoviocytes. Their 3D chitosan hydrogel matrix is not only pivotal for cartilage repair but is also utilized in cell culture applications to enhance the understanding of osteoarthrosis and other related conditions. This comprehensive approach positions ACS Biotech as a key player in the field of regenerative medicine, with a strong emphasis on innovation and quality in their cellular-based therapy products.

France

ACS Biotech vision is to change the lives of millions of people suffering from osteoarticular pathologies through regenerative medicine and development of new cellular-based products.

Our solution for cartilage repair, aims to regenerate articular cartilage damage with our Cartilage gel with only one precise and mini-invasive surgery, practised by specialized orthopaedic surgeons. A few months later, patients could remain their mobility and sportive activities.

ACS Biotech

Company Details